EUVIMEDEUVIMED entdecken
Crossref

28-PUB: Food Tracking Frequency and Clinically Meaningful Glucose Improvements among Real-World OTC CGM Users with Hyperglycemia

AMY MCKENZIE, ALAN J. WILK

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-28-pub ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von AMY MCKENZIE und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Over-the-counter continuous glucose monitors (CGMs) help users understand how food impacts glucose, supporting behavior change to improve glycemia. This study assessed the relationship between food tracking behavior and clinically meaningful glycemic improvements among individuals with hyperglycemia using real-world data.

Methods

People with hyperglycemia who wore six Lingo CGMs over 65-135 days were grouped by frequency of food tracking (>50% vs ≤50% sensor days). Clinically meaningful improvement was defined as ≥14 mg/dL reduction in mean glucose or ≥ 5% reduction in time above 140 mg/dL (TA140) between the first and sixth sensor. Relationships between logging frequency and glycemic improvements were assessed with logistic regression odds ratios (OR) adjusting for demographics for those with first sensor mean glucose 117-140 mg/dL and, separately, >140 mg/dL.

Results

More frequent food trackers (>50% sensor days) with first sensor mean glucose 117-140 mg/dL (n=115 of 992) were nearly twice as likely to see meaningful reductions in mean glucose (30 vs 19%, OR=1.9 [1.2, 3.0]) and TA140 (55 vs 42%, OR=1.7 [1.2, 2.6]). In more and less frequent trackers, respectively, mean glucose reduced by 7 (14) and 1 (20) mg/dL (p < 0.001) and TA140 decreased by 6 (13) and increased by 2 (19) % (p < 0.001). Among those with first sensor mean glucose >140 mg/dL, more frequent trackers (n=30 of 662) had no statistical difference in odds of improvement or reduction of mean glucose (53 vs 41%, OR=1.7 [0.8,3.5]; 23 (36) vs 11 (40) mg/dL, p = 0.097), but had significantly greater reductions in TA140 (70 vs 54%, OR=2.0 [0.9, 4.3]; 23 (30) vs 12 (26)%, p = 0.028).

Conclusion

These data are among the first to demonstrate a relationship between food tracking and improved CGM metrics of glycemia in real-world users with hyperglycemia. These findings suggest people may be encouraged to track foods while wearing a CGM, as this may facilitate better understanding of the relative impact of different foods on glucose to inform future decisions. Disclosure A. McKenzie: Employee; Current; Abbott. Stock/Shareholder; Current; Abbott, Virta Health Corp. A.J. Wilk: Employee; Current; Abbott Diagnostics.

Zitieren

APA

MCKENZIE, A., & WILK, A. J. (2026). 28-PUB: Food Tracking Frequency and Clinically Meaningful Glucose Improvements among Real-World OTC CGM Users with Hyperglycemia. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-28-pub

Vancouver

MCKENZIE A, WILK AJ. 28-PUB: Food Tracking Frequency and Clinically Meaningful Glucose Improvements among Real-World OTC CGM Users with Hyperglycemia. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-28-pub

BibTeX
@article{MCKENZIE2026,
  author = {MCKENZIE, AMY and WILK, ALAN J.},
  title = {28-PUB: Food Tracking Frequency and Clinically Meaningful Glucose Improvements among Real-World OTC CGM Users with Hyperglycemia},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-28-pub}
}
Kostenlos starten →